Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion received final marketing approval from the U.S. FDA for Omlyclo (CT-P39), a biosimilar to Xolair, covering all indications held by the reference product.
📊 Key Disclosure Content & Financial Highlights
- Overview
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Major Matters Report Related to Investment Decisions
- Subject: U.S. FDA Final Marketing Approval for Omlyclo (CT-P39, Xolair Biosimilar)
- Regulatory Body: U.S. Food and Drug Administration (FDA)
- Application & Approval Dates (Local Time): Application Date 2024-03-08 / Approval Date 2025-03-07
- Confirmation Date: 2025-03-08 (Receipt date of FDA approval letter)
- Product & Indication Details
- Product Name: Omlyclo (CT-P39, Active Ingredient: Omalizumab)
- Approved Indications:
- Asthma
- Chronic Rhinosinusitis with Nasal Polyps
- Chronic Spontaneous Urticaria
- IgE-Mediated Food Allergy
- Key Details & Future Plans
- Approval Details: Secured final U.S. marketing authorization for all indications approved for the reference product (Xolair)
- Expected Effects: Expanded treatment options for patients by securing authorization across all reference indications
- Future Plans: Distribution throughout the U.S. via local subsidiary
- Additional Notes: Content will be utilized in future press releases and IR materials
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Final FDA Approval Listing in Official Documents
This disclosure serves as official notification regarding FDA marketing approval for Omlyclo across all reference drug indications. Reviewing whether the final marketing authorization status is accurately reflected in the company’s official periodic reporting documents is important for verifying the formal regulatory documentation. Relevant updates can be confirmed through subsequent periodic reports or official IR materials.
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
